Table 3.
Association of HLA-B alleles with carbamazepine-induced MPE.
| HLA-B alleles | Carbamazepine-induced MPE (n = 17) | Controls (n = 271) | Thai population (n = 470) | Carbamazepine-induced MPE cases versus tolerant controls | Carbamazepine-induced MPE cases versus Thai population | ||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||||
| B∗07:05 | 1 (5.88%) | 12 (4.43%) | 24 (5.11%) | 1.44 (0.18–11.81) | 0.533 | 1.234 (0.16–9.78) | 0.576 |
| B∗13:02 | 1 (5.88%) | 6 (2.21%) | 20 (4.26%) | 2.94 (0.33–26.05) | 0.334 | 1.50 (0.19–11.93) | 0.512 |
| B∗15:02 | 4 (23.52%) | 11 (4.06%) | 71 (15.11%) | 7.27 (2.04–25.97) | 0.002∗ | 2.30 (0.36–4.67) | 0.721 |
| B∗18:01 | 1 (5.88%) | 29 (10.70%) | 36 (7.66%) | 0.19 (0.03–1.40) | 0.098 | 0.80 (0.10–6.26) | 1.000 |
| B∗18:15 | 1 (5.88%) | 0 (0.00%) | 0 (0.00%) | 18.07 (1.08–303.14) | 0.108 | 31.33 (1.87–525.19) | 0.065 |
| B∗27:04 | 1 (5.88%) | 12 (4.43%) | 19 (4.04%) | 1.44 (0.18–11.81) | 0.533 | 1.58 (0.20–12.61) | 0.495 |
| B∗40:01 | 3 (17.65%) | 41 (15.13%) | 58 (12.34%) | 1.30 (0.35–4.74) | 0.720 | 1.64 (0.45–5.93) | 0.438 |
| B∗44:03 | 2 (11.77%) | 20 (7.38%) | 42 (8.94%) | 1.72 (0.37–8.11) | 0.369 | 1.46 (0.32–6.62) | 0.648 |
| B∗46 :01 | 3 (17.65%) | 64 (23.62%) | 122 (25.96%) | 0.69 (0.19–2.49) | 0.574 | 0.66 (0.18–2.35) | 0.772 |
| B∗51:01 | 3 (17.65%) | 21 (7.75%) | 40 (8.51%) | 2.55 (0.69–9.60) | 0.166 | 2.30 (0.65–8.35) | 0.204 |
| B∗57:01 | 1 (5.88%) | 9 (3.32%) | 11 (2.34%) | 1.94 (0.23–16.34) | 0.442 | 2.78 (0.34–22.96) | 0.334 |
| B∗58:01 | 5 (29.41%) | 22 (8.12%) | 57 (12.13%) | 4.74 (1.53–14.66) | 0.007∗ | 3.03 (1.03–8.88) | 0.045∗ |
MPE: maculopapular exanthema; OR: odds ratio; 95% CI: confidence interval 95%. ∗P value less than 0.05.